References
- Naik S, Russell SJ. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther 2009; 9:1163 - 76; http://dx.doi.org/10.1517/14712590903170653; PMID: 19637971
- Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011; 477:99 - 102; http://dx.doi.org/10.1038/nature10358; PMID: 21886163
- Prestwich RJ, Errington F, Diaz RM, Pandha H, Harrington KJ, Melcher AA, et al. The Case of Oncolytic Viruses vs The Immune System: Waiting On The Judgment of Solomon. Hum Gene Ther 2009; 20:1119 - 32; http://dx.doi.org/10.1089/hum.2009.135; PMID: 19630549
- Woller N, Knocke S, Mundt B, Gurlevik E, Struver N, Kloos A, et al. Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice. J Clin Invest 2011; 121:2570 - 82; http://dx.doi.org/10.1172/JCI45585; PMID: 21646722
- Lund JM, Hsing L, Pham TT, Rudensky AY. Coordination of early protective immunity to viral infection by regulatory T cells. Science 2008; 320:1220 - 4; http://dx.doi.org/10.1126/science.1155209; PMID: 18436744
- Sharma MD, Hou DY, Baban B, Koni PA, He Y, Chandler PR, et al. Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity 2010; 33:942 - 54; http://dx.doi.org/10.1016/j.immuni.2010.11.022; PMID: 21145762
- Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E, et al. Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther 2010; 18:1430 - 9; http://dx.doi.org/10.1038/mt.2010.98; PMID: 20551919
- Kottke T, Errington F, Pulido J, Galivo F, Thompson J, Wongthida P, et al. Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat Med 2011; 17:854 - 9; http://dx.doi.org/10.1038/nm.2390; PMID: 21685898
- Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050 - 9; http://dx.doi.org/10.1038/nm1622; PMID: 17704786
- Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011; 17:1094 - 100; http://dx.doi.org/10.1038/nm.2438; PMID: 21873989